WRAP TECHNOLOGIES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that WRAP TECHNOLOGIES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.67M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.51M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.13M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.05M | Aug 28, 2024 |
| FY2022 | Sep 30, 2022 | $8.05M | Mar 2, 2023 |
| FY2022 | Dec 31, 2021 | $7.73M | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | $7.73M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $3.94M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $696.8K | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $23.2K | Mar 10, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.70M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.47M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.91M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.73M | Aug 28, 2024 |
| FY2022 | Sep 30, 2022 | $911.0K | Nov 9, 2022 |
| FY2022 | Dec 31, 2021 | $2.00M | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | $711.0K | Nov 9, 2022 |
| FY2021 | Dec 31, 2020 | $1.34M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $276.8K | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $4.5K | Mar 10, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.34M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($5.88M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($30.22M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($17.62M) | Aug 28, 2024 |
| FY2022 | Sep 30, 2022 | ($3.87M) | Nov 9, 2022 |
| FY2022 | Dec 31, 2021 | ($24.45M) | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | ($5.99M) | Nov 9, 2022 |
| FY2021 | Dec 31, 2020 | ($12.58M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($8.33M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($3.34M) | Mar 10, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.49M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($15.57M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($18.72M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($17.73M) | Aug 28, 2024 |
| FY2022 | Sep 30, 2022 | ($3.91M) | Nov 9, 2022 |
| FY2022 | Dec 31, 2021 | ($24.50M) | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | ($6.02M) | Nov 9, 2022 |
| FY2021 | Dec 31, 2020 | ($13.08M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($8.61M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($3.34M) | Mar 10, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.34M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $3.27M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.08M | Aug 28, 2024 |
| FY2022 | Sep 30, 2022 | $1.24M | Nov 9, 2022 |
| FY2022 | Dec 31, 2021 | $6.21M | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | $2.08M | Nov 9, 2022 |
| FY2021 | Dec 31, 2020 | $2.79M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $2.24M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $734.8K | Mar 10, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.13M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $15.69M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $18.36M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $16.39M | Aug 28, 2024 |
| FY2022 | Sep 30, 2022 | $3.59M | Nov 9, 2022 |
| FY2022 | Dec 31, 2021 | $20.28M | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | $4.65M | Nov 9, 2022 |
| FY2021 | Dec 31, 2020 | $11.63M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $6.65M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $2.61M | Mar 10, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.29M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($8.13M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($16.70M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($14.60M) | Aug 28, 2024 |
| FY2022 | Sep 30, 2022 | ($11.04M) | Nov 9, 2022 |
| FY2022 | Dec 31, 2021 | ($18.22M) | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | ($13.73M) | Nov 9, 2022 |
| FY2021 | Dec 31, 2020 | ($12.19M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($8.49M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($2.69M) | Mar 10, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $12.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $230.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $256.0K | Aug 28, 2024 |
| FY2022 | Sep 30, 2022 | $201.0K | Nov 9, 2022 |
| FY2022 | Dec 31, 2021 | $995.0K | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | $811.0K | Nov 9, 2022 |
| FY2021 | Dec 31, 2020 | $249.0K | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $256.7K | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $14.2K | Mar 10, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.42M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $15.12M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $28.50M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $30.57M | Aug 28, 2024 |
| FY2022 | Sep 30, 2022 | $32.52M | Nov 9, 2022 |
| FY2022 | Dec 31, 2021 | $44.23M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $48.83M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $20.42M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $12.79M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $3.26M | Mar 7, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.93M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $14.87M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $25.34M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.52M | Aug 28, 2024 |
| FY2022 | Sep 30, 2022 | $2.56M | Nov 9, 2022 |
| FY2022 | Dec 31, 2021 | $2.97M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $2.42M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $1.23M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $397.4K | Mar 10, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.49M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $250.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $3.16M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $27.06M | Mar 31, 2025 |
| FY2022 | Sep 30, 2022 | $29.96M | Nov 9, 2022 |
| FY2022 | Jun 30, 2022 | $32.87M | Nov 9, 2022 |
| FY2022 | Dec 31, 2021 | $41.26M | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | $45.46M | Nov 9, 2022 |
| FY2022 | Jun 30, 2021 | $48.76M | Nov 9, 2022 |
| FY2022 | Dec 31, 2020 | $46.41M | Mar 2, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.61M | Mar 26, 2026 |
| FY2024 | Aug 31, 2023 | $1.61M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Aug 28, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($116.32M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($105.08M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($97.99M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($67.38M) | Aug 28, 2024 |
| FY2022 | Sep 30, 2022 | ($63.84M) | Nov 9, 2022 |
| FY2022 | Dec 31, 2021 | ($49.76M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($25.31M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($12.73M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($4.40M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($1.07M) | Mar 7, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.47M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.61M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $3.96M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.33M | Aug 28, 2024 |
| FY2022 | Sep 30, 2022 | $3.83M | Nov 9, 2022 |
| FY2023 | Dec 31, 2021 | $4.94M | Aug 28, 2024 |
| FY2022 | Sep 30, 2021 | $9.86M | Nov 9, 2022 |
| FY2022 | Dec 31, 2020 | $16.65M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $16.98M | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $12.36M | Mar 4, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Aug 28, 2024 |
| FY2022 | Sep 30, 2022 | 0 | Nov 9, 2022 |
| FY2022 | Dec 31, 2021 | 0 | Mar 2, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Nov 9, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Mar 7, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 6, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 51.73M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 47.10M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 43.86M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 41.18M | Aug 28, 2024 |
| FY2022 | Sep 30, 2022 | 41.13M | Nov 9, 2022 |
| FY2022 | Dec 31, 2021 | 40.85M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | 37.55M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 29.83M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | 27.36M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | 22.80M | Mar 7, 2019 |